Yyy-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

angelala
2021-02-05

Yyy

Nuohui Health will launch its IPO today, and the admission fee is about HK $13,464.33

2月5日消息，诺辉健康-B 公布招股详情，计划发行7,659.8万股，当中约90%即约6,893.8万股为国际配售，约10%即约766万股为本地公开发售，另设15%超额配股权。招股价介乎每股22.7至

Nuohui Health will launch its IPO today, and the admission fee is about HK $13,464.33

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":380962894,"tweetId":"380962894","gmtCreate":1612505159518,"gmtModify":1704872100089,"author":{"id":3569217644250851,"idStr":"3569217644250851","authorId":3569217644250851,"authorIdStr":"3569217644250851","name":"angelala","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Yyy</p></body></html>","htmlText":"<html><head></head><body><p>Yyy</p></body></html>","text":"Yyy","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/380962894","repostId":1194873125,"repostType":4,"repost":{"id":"1194873125","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1612484798,"share":"https://ttm.financial/m/news/1194873125?lang=en_US&edition=fundamental","pubTime":"2021-02-05 08:26","market":"hk","language":"zh","title":"Nuohui Health will launch its IPO today, and the admission fee is about HK $13,464.33","url":"https://stock-news.laohu8.com/highlight/detail?id=1194873125","media":"老虎资讯综合","summary":"2月5日消息，诺辉健康-B 公布招股详情，计划发行7,659.8万股，当中约90%即约6,893.8万股为国际配售，约10%即约766万股为本地公开发售，另设15%超额配股权。招股价介乎每股22.7至","content":"<p>News on February 5,<a href=\"https://laohu8.com/S/06606\">Nuohui Health-B</a>Announcing the details of the IPO, it is planned to issue 76.598 million shares, of which approximately 90%, or approximately 68.938 million shares, will be placed internationally, approximately 10%, or approximately 7.66 million shares, will be placed locally, and there will be a 15% over-allotment option. The offering price ranges from 22.7 to 26.66 yuan per share, and the maximum fund raised is about 2.042 billion yuan. Excluding handling fees, the admission fee for each lot of 500 shares is approximately HK $13,464.33. The company will issue an IPO from today (February 5th) to next Wednesday (10th), and is expected to be listed on February 18th. The company's joint sponsors are Goldman Sachs and UBS.</p><p><b>Tiger's new channel opens at 11:30 noon today!</b><a href=\"https://www.itiger.com/mi/ipo/listing/hk\" target=\"_blank\"><b>Go play new < < <</b></a><b></b></p><p><img src=\"https://static.tigerbbs.com/29b28d7ae772300f67d2d9a4fc46fcdd\" tg-width=\"743\" tg-height=\"543\" referrerpolicy=\"no-referrer\">It is reported that Nuohui Health was established in November 2015 and is a pioneer in China's colorectal cancer screening market. It aims to promote technological innovation and accelerate the adoption of cancer screening technology in China.</p><p>According to Frost & Sullivan, the company's proprietary non-invasive multi-target FIT-DNA test, Chang Weiqing, is China's first and only molecular cancer screening test product approved by the State Food and Drug Administration. The company focuses on designing, developing and commercializing cancer screening tests. Its two home-based colorectal cancer screening test products, Changweiqing and Pupu Tube, collaborate to deal with target groups with different risk levels.</p><p><img src=\"https://static.tigerbbs.com/666d0210f8191dc62dbf532fc0d676e1\" tg-width=\"1104\" tg-height=\"630\" referrerpolicy=\"no-referrer\"></p><p><b>Financial status,</b>In the fiscal year 2018 ~ 2019, the company recorded a total revenue of HK $18.816 million and HK $58.275 million respectively, a year-on-year increase of 209.7%, and net losses during the same period were HK $224.9 million and HK $106.5 million respectively; In the first nine months ended September 30 in 2019 and 2020, the total revenue was HK $35.44 million and HK $35.309 million respectively, and the net losses during the same period were HK $62.508 million and HK $530 million respectively.</p><p><img src=\"https://static.tigerbbs.com/b9f861b31969ad8b9f34416a9a7787a1\" tg-width=\"874\" tg-height=\"772\" referrerpolicy=\"no-referrer\"></p><p><b>Industry terms,</b>China has the highest incidence of colorectal cancer in the world, with 388,000 confirmed cases in 2015 increasing to 440,000 confirmed cases in 2019, with a compound annual growth rate of 3.2%. According to Frost & Sullivan, the cost of colorectal cancer treatment imposes a heavy economic burden on China's healthcare system, with overall per capita expenditure being the highest among the types of cancer common in urban areas in China.</p><p>Colorectal cancer is one of the few cancer types recommended for regular screening among intermediate-risk people without signs or symptoms of cancer due to high incidence, high mortality, long tumor development cycle and heavy treatment burden.</p><p><img src=\"https://static.tigerbbs.com/14aea1711b4164a44334fb97235ca3ee\" tg-width=\"698\" tg-height=\"448\" referrerpolicy=\"no-referrer\"></p><p><b>As for cornerstone investors,</b>A number of cornerstone investors agreed to subscribe for the number of offer shares available for subscription at the offer price, totaling approximately US $124 million, including: Invesco Advisers, Inc, Lake Bleu Prime Healthcare Master Fund Limited, Qingchi Capital, GIC, Southern Fund, etc.</p><p><b>In terms of financing purposes, the company plans to</b></p><p><ul><li>Approximately 40% of which is used to fund the commercialization and further development of the product ColoClear;</li><li>Approximately 30% is used to fund ongoing and planned early stage pipeline product research and development; About 15% will be used for potential acquisition or external introduction of product candidates in the field of cancer screening;</li><li>Approximately 5% is used to fund the ongoing sales and marketing of the product Pupu Tube;</li><li>And approximately 10% for general working capital.</li></ul></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuohui Health will launch its IPO today, and the admission fee is about HK $13,464.33</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuohui Health will launch its IPO today, and the admission fee is about HK $13,464.33\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-02-05 08:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>News on February 5,<a href=\"https://laohu8.com/S/06606\">Nuohui Health-B</a>Announcing the details of the IPO, it is planned to issue 76.598 million shares, of which approximately 90%, or approximately 68.938 million shares, will be placed internationally, approximately 10%, or approximately 7.66 million shares, will be placed locally, and there will be a 15% over-allotment option. The offering price ranges from 22.7 to 26.66 yuan per share, and the maximum fund raised is about 2.042 billion yuan. Excluding handling fees, the admission fee for each lot of 500 shares is approximately HK $13,464.33. The company will issue an IPO from today (February 5th) to next Wednesday (10th), and is expected to be listed on February 18th. The company's joint sponsors are Goldman Sachs and UBS.</p><p><b>Tiger's new channel opens at 11:30 noon today!</b><a href=\"https://www.itiger.com/mi/ipo/listing/hk\" target=\"_blank\"><b>Go play new < < <</b></a><b></b></p><p><img src=\"https://static.tigerbbs.com/29b28d7ae772300f67d2d9a4fc46fcdd\" tg-width=\"743\" tg-height=\"543\" referrerpolicy=\"no-referrer\">It is reported that Nuohui Health was established in November 2015 and is a pioneer in China's colorectal cancer screening market. It aims to promote technological innovation and accelerate the adoption of cancer screening technology in China.</p><p>According to Frost & Sullivan, the company's proprietary non-invasive multi-target FIT-DNA test, Chang Weiqing, is China's first and only molecular cancer screening test product approved by the State Food and Drug Administration. The company focuses on designing, developing and commercializing cancer screening tests. Its two home-based colorectal cancer screening test products, Changweiqing and Pupu Tube, collaborate to deal with target groups with different risk levels.</p><p><img src=\"https://static.tigerbbs.com/666d0210f8191dc62dbf532fc0d676e1\" tg-width=\"1104\" tg-height=\"630\" referrerpolicy=\"no-referrer\"></p><p><b>Financial status,</b>In the fiscal year 2018 ~ 2019, the company recorded a total revenue of HK $18.816 million and HK $58.275 million respectively, a year-on-year increase of 209.7%, and net losses during the same period were HK $224.9 million and HK $106.5 million respectively; In the first nine months ended September 30 in 2019 and 2020, the total revenue was HK $35.44 million and HK $35.309 million respectively, and the net losses during the same period were HK $62.508 million and HK $530 million respectively.</p><p><img src=\"https://static.tigerbbs.com/b9f861b31969ad8b9f34416a9a7787a1\" tg-width=\"874\" tg-height=\"772\" referrerpolicy=\"no-referrer\"></p><p><b>Industry terms,</b>China has the highest incidence of colorectal cancer in the world, with 388,000 confirmed cases in 2015 increasing to 440,000 confirmed cases in 2019, with a compound annual growth rate of 3.2%. According to Frost & Sullivan, the cost of colorectal cancer treatment imposes a heavy economic burden on China's healthcare system, with overall per capita expenditure being the highest among the types of cancer common in urban areas in China.</p><p>Colorectal cancer is one of the few cancer types recommended for regular screening among intermediate-risk people without signs or symptoms of cancer due to high incidence, high mortality, long tumor development cycle and heavy treatment burden.</p><p><img src=\"https://static.tigerbbs.com/14aea1711b4164a44334fb97235ca3ee\" tg-width=\"698\" tg-height=\"448\" referrerpolicy=\"no-referrer\"></p><p><b>As for cornerstone investors,</b>A number of cornerstone investors agreed to subscribe for the number of offer shares available for subscription at the offer price, totaling approximately US $124 million, including: Invesco Advisers, Inc, Lake Bleu Prime Healthcare Master Fund Limited, Qingchi Capital, GIC, Southern Fund, etc.</p><p><b>In terms of financing purposes, the company plans to</b></p><p><ul><li>Approximately 40% of which is used to fund the commercialization and further development of the product ColoClear;</li><li>Approximately 30% is used to fund ongoing and planned early stage pipeline product research and development; About 15% will be used for potential acquisition or external introduction of product candidates in the field of cancer screening;</li><li>Approximately 5% is used to fund the ongoing sales and marketing of the product Pupu Tube;</li><li>And approximately 10% for general working capital.</li></ul></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/03b737852f586e2640047e4e68a010a4","relate_stocks":{"06606":"诺辉健康"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194873125","content_text":"2月5日消息，诺辉健康-B 公布招股详情，计划发行7,659.8万股，当中约90%即约6,893.8万股为国际配售，约10%即约766万股为本地公开发售，另设15%超额配股权。招股价介乎每股22.7至26.66元，集资最多约20.42亿元。未计手续费，每手500股入场费约13,464.33港元。该公司将于今日（2月5日）起至下周三(10日)招股，预期2月18日挂牌上市。公司联席保荐人为高盛、瑞银。老虎打新通道今天中午11:30开通！去打新<<<据悉，诺辉健康于2015年11月成立，是中国结直肠癌筛查市场的先行者，旨在推进技术创新，并加快癌症筛查技术于中国的采用。根据弗若斯特沙利文，公司专有的非侵入性多靶点FIT-DNA测试-常卫清为中国首个且唯一一个获国家药监局批准的分子癌症筛查测试产品。公司专注于设计、开发癌症筛查测试及将其商业化，其两大居家结直肠癌筛查测试产品常卫清及噗噗管协同处理不同风险程度的目标人群。财务状况方面，于2018~2019财年，公司共录得的总收入分别为1881.6万和5827.5万港元，同比增长209.7%，同期净亏损分别为2.249亿、1.065亿港元；2019年、2020年的截至9月30止的前九个月，总收入分别为3544万、3530.9万港元，同期净亏损分别为6250.8万、5.3亿港元。行业方面，中国是全球结直肠癌发病数最高的国家，2015年的38.8万宗确诊病例增加至2019年的44万宗确诊病例，复合年增长率为3.2%。根据弗若斯特沙利文，结直肠癌的治疗成本为中国医疗体系带来沉重的经济负担，整体人均开支于中国城市地区常见的癌症类型中为最高。由于发病数高、死亡数高、肿瘤发展周期长及治疗负担沉重，结直肠癌在无癌症体征或症状的中等风险人群中属于少数建议定期筛查的癌症类型之一。基石投资者方面，多名基石投资者同意按发售价认购可供认购的发售股份数目，总额约1.24亿美元，包括：Invesco Advisers, Inc、Lake Bleu Prime Healthcare Master Fund Limited、清池资本、GIC 、南方基金等。筹资用途方面，公司拟将当中约40%用于为产品「常卫清」的商业化及进一步开发提供资金；约30%用于为正在进行及计划进行的早期阶段管线产品研发提供资金；约15%将用于潜在收购或外部引进癌症筛查领域的候选产品；约5%用于为产品「噗噗管」的持续销售及营销提供资金；以及约10%为一般营运资金。","news_type":1,"symbols_score_info":{"06606":0.9}},"isVote":1,"tweetType":1,"viewCount":2058,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}